Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$108.02M+86315.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Curran Simpson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 0.93
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.98
Financials
Revenue
$108.02M+86315.2%Net Income
$22.71MEBITDA
$34.26MFree Cash Flow
$-63.00MEPS (diluted)
$0.43Shares Outstanding (diluted)
53.02M+100.3%Operating Expenses
$77.70MCash & Debt
$105.52MReturn of Capital
$0.00Revenue by Segment (annual)
$170.44MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.44M | $-193.88M | $-3.76 |
| 2024 | $83.33M | $-227.10M | $-4.59 |
| 2023 | $90.24M | $-263.49M | $-6.02 |
| 2022 | $112.72M | $-280.32M | $-6.50 |
| 2021 | $470.35M | $127.84M | $3.01 |
| 2020 | $154.57M | $-111.25M | $-2.98 |
| 2019 | $35.23M | $-94.73M | $-2.58 |
| 2018 | $218.50M | $99.94M | $2.73 |
| 2017 | $10.39M | $-73.17M | $-2.45 |
| 2016 | $4.59M | $-62.97M | $-2.38 |
| 2015 | $7.59M | $-22.81M | $-2.49 |
| 2014 | $6.12M | $-4.00M | $-0.30 |
| 2013 | $6.09M | $-5.39M | $-2.04 |
Valuation
RGNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57+7.94%Social Signal Score
Mentions (10)
- Newsprnewswire.com·11d ago·Neutral
…tment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·28d ago·Neutral
REGENXBIO to Participate in Upcoming Investor Conferences ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.
View source ↗ - Newszacks.com·41d ago·Negative
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
View source ↗ - Newsseekingalpha.com·41d ago·Negative
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
View source ↗ - Newsprnewswire.com·42d ago·Neutral
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
View source ↗ - Newsbarrons.com·43d ago·Neutral
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
View source ↗ - Newsreuters.com·43d ago·Negative
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.
View source ↗ - Newsprnewswire.com·43d ago·Neutral
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
View source ↗ - Newsseekingalpha.com·55d ago·Neutral
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-1.21 per share
Typical surprise -22.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.43 vs $0.08beat
- Thu, May 14$-1.72 vs $-1.36miss
- Thu, Mar 5$-1.30 vs $-1.01miss
- Thu, Nov 6$-1.20 vs $-1.38beat
- Thu, Aug 7$-1.38 vs $-1.13miss
- Mon, May 12$0.12 vs $0.41miss
Estimates and results for RGNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RGNX officers and directors.
- Bought
- $949k
- Sold
- $1.5m
2 trades
9 trades
- Ciongoli Gregory Austinbought
- Ciongoli Gregory Austinbought
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Simpson Curransold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Peter Welchhouse · VT00 · disclosed Nov 14, 2019 (23d later)Buy$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Nov 14, 2019 (6d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.